{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:21:42Z","timestamp":1783642902830,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10183-2","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:36:38Z","timestamp":1777995398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Senescent endothelial cell-derived extracellular vesicles promote neoadjuvant chemoresistance in colorectal cancer via GPX4"],"prefix":"10.1038","volume":"9","author":[{"given":"Kunpeng","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-3156","authenticated-orcid":false,"given":"Fengbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-5007","authenticated-orcid":false,"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7483-4380","authenticated-orcid":false,"given":"Yeting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-7042","authenticated-orcid":false,"given":"Zhigang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"10183_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"10183_CR2","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/cancers16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel, G., Ghasemi-Kebria, F. & Malekzadeh, R. Colorectal cancer: epidemiology, risk factors, and prevention. Cancers 16, 1530 (2024).","journal-title":"Cancers"},{"key":"10183_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19173-2","volume":"11","author":"Y-H Cho","year":"2020","unstructured":"Cho, Y.-H. et al. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT\/\u03b2-catenin pathway activation. Nat. Commun. 11, 5321 (2020).","journal-title":"Nat. Commun."},{"key":"10183_CR4","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler, J. P. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25, 2198\u20132204 (2007).","journal-title":"J. Clin. Oncol."},{"key":"10183_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36334-1","volume":"14","author":"J Linares","year":"2023","unstructured":"Linares, J. et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nat. Commun. 14, 746 (2023).","journal-title":"Nat. Commun."},{"key":"10183_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2006.07.4187","volume":"25","author":"M Del Rio","year":"2007","unstructured":"Del Rio, M. et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25, 773\u2013780 (2007).","journal-title":"J. Clin. Oncol."},{"key":"10183_CR7","doi-asserted-by":"publisher","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","volume":"4","author":"A Cercek","year":"2018","unstructured":"Cercek, A. et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 4, e180071 (2018).","journal-title":"JAMA Oncol."},{"key":"10183_CR8","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald, J. A., Desotelle, J. A., Wilding, G. & Jarrard, D. F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 102, 1536\u20131546 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"10183_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.aaw1299","volume":"364","author":"JM van Deursen","year":"2019","unstructured":"van Deursen, J. M. Senolytic therapies for healthy longevity. Science 364, 636\u2013637 (2019).","journal-title":"Science"},{"key":"10183_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813\u2013827 (2019).","journal-title":"Cell"},{"key":"10183_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"10183_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359\u20131368 (2012).","journal-title":"Nat. Med."},{"key":"10183_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"10183_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","volume":"153","author":"A Lujambio","year":"2013","unstructured":"Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449\u2013460 (2013).","journal-title":"Cell"},{"key":"10183_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41580-018-0068-0","volume":"19","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., Yamazaki, T. & Kroemer, G. Linking cellular stress responses to systemic homeostasis. Nat. Rev. Mol. Cell Biol. 19, 731\u2013745 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10183_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrm3823","volume":"15","author":"D Mu\u00f1oz-Esp\u00edn","year":"2014","unstructured":"Mu\u00f1oz-Esp\u00edn, D. & Serrano, M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482\u2013496 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10183_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3390\/medicina59091646","volume":"59","author":"VA Ionescu","year":"2023","unstructured":"Ionescu, V. A., Gheorghe, G., Bacalbasa, N., Chiotoroiu, A. L. & Diaconu, C. Colorectal cancer: from risk factors to oncogenesis. Medicina 59, 1646 (2023).","journal-title":"Medicina"},{"key":"10183_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112197","volume":"134","author":"Y Yue","year":"2024","unstructured":"Yue, Y. et al. A novel senescence-based prognostic model unveils tumor interactions and drug resistance in colorectal cancer. Int. Immunopharmacol. 134, 112197 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"10183_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.15252\/embr.201439245","volume":"15","author":"BG Childs","year":"2014","unstructured":"Childs, B. G., Baker, D. J., Kirkland, J. L., Campisi, J. & van Deursen, J. M. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep. 15, 1139\u20131153 (2014).","journal-title":"EMBO Rep."},{"key":"10183_CR20","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/ijms23063002","volume":"23","author":"M Porika","year":"2022","unstructured":"Porika, M., Tippani, R. & Saretzki, G. C. CRISPR\/Cas: a new tool in the research of telomeres and telomerase as well as a novel form of cancer therapy. Int. J. Mol. Sci. 23, 3002 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"10183_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644\u2013658 (2015).","journal-title":"Aging Cell"},{"key":"10183_CR22","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1002\/1878-0261.13312","volume":"16","author":"L Bousset","year":"2022","unstructured":"Bousset, L. & Gil, J. Targeting senescence as an anticancer therapy. Mol. Oncol. 16, 3855\u20133880 (2022).","journal-title":"Mol. Oncol."},{"key":"10183_CR23","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, 6977 (2020).","journal-title":"Science"},{"key":"10183_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654\u2013659 (2007).","journal-title":"Nat. Cell Biol."},{"key":"10183_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15287","volume":"8","author":"A Takahashi","year":"2017","unstructured":"Takahashi, A. et al. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat. Commun. 8, 15287 (2017).","journal-title":"Nat. Commun."},{"key":"10183_CR26","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.7150\/thno.25541","volume":"8","author":"J Ren","year":"2018","unstructured":"Ren, J. et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics 8, 3932\u20133948 (2018).","journal-title":"Theranostics"},{"key":"10183_CR27","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1002\/jcp.29585","volume":"235","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J. Cell. Physiol. 235, 6896\u20136904 (2020).","journal-title":"J. Cell. Physiol."},{"key":"10183_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02331-9","volume":"22","author":"B Hui","year":"2024","unstructured":"Hui, B. et al. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085. J. Nanobiotechnology 22, 62 (2024).","journal-title":"J. Nanobiotechnology"},{"key":"10183_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-024-01985-1","volume":"23","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Therapy-induced senescent tumor cell-derived extracellular vesicles promote colorectal cancer progression through SERPINE1-mediated NF-\u03baB p65 nuclear translocation. Mol. Cancer 23, 70 (2024).","journal-title":"Mol. Cancer"},{"key":"10183_CR30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"D Sj","year":"2012","unstructured":"Sj, D. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"10183_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"Y Ws","year":"2014","unstructured":"Ws, Y. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"10183_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41420-024-01938-z","volume":"10","author":"J Wu","year":"2024","unstructured":"Wu, J., Li, Z., Wu, Y. & Cui, N. The crosstalk between exosomes and ferroptosis: a review. Cell Death Discov. 10, 170 (2024).","journal-title":"Cell Death Discov."},{"key":"10183_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct. Target. Ther. 9, 55 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10183_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"key":"10183_CR35","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).","journal-title":"Pharmacol. Ther."},{"key":"10183_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A. & Fares, Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct. Target. Ther. 5, 28 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10183_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101231","volume":"4","author":"P Qin","year":"2023","unstructured":"Qin, P. et al. Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics. Cell Rep. Med. 4, 101231 (2023).","journal-title":"Cell Rep. Med."},{"key":"10183_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/jgo-20-220","volume":"11","author":"CK Cheong","year":"2020","unstructured":"Cheong, C. K. et al. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. J. Gastrointest. Oncol. 11, 847\u2013857 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"10183_CR39","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S1470-2045(12)70348-0","volume":"13","author":"Foxtrot Collaborative Group","year":"2012","unstructured":"Foxtrot Collaborative Group null. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 13, 1152\u20131160 (2012).","journal-title":"Lancet Oncol."},{"key":"10183_CR40","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3109\/0284186X.2015.1037007","volume":"54","author":"A Jakobsen","year":"2015","unstructured":"Jakobsen, A. et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncol. 54, 1747\u20131753 (2015).","journal-title":"Acta Oncol."},{"key":"10183_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12094-016-1539-4","volume":"19","author":"J Arredondo","year":"2017","unstructured":"Arredondo, J. et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin. Transl. Oncol. 19, 379\u2013385 (2017).","journal-title":"Clin. Transl. Oncol."},{"key":"10183_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/OTT.S150367","volume":"11","author":"H Chang","year":"2018","unstructured":"Chang, H. et al. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 11, 409\u2013418 (2018).","journal-title":"Onco Targets Ther."},{"key":"10183_CR43","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1200\/JCO.23.01889","volume":"42","author":"H Hu","year":"2024","unstructured":"Hu, H. et al. Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, Phase III OPTICAL Trial. J. Clin. Oncol. 42, 2978\u20132988 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10183_CR44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Preoperative treatment of locally advanced rectal cancer. N. Engl. J. Med. 389, 322\u2013334 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10183_CR45","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1200\/JCO.2016.66.6198","volume":"34","author":"Y Deng","year":"2016","unstructured":"Deng, Y. et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J. Clin. Oncol. 34, 3300\u20133307 (2016).","journal-title":"J. Clin. Oncol."},{"key":"10183_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","volume":"32","author":"D Schrag","year":"2014","unstructured":"Schrag, D. et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J. Clin. Oncol. 32, 513\u2013518 (2014).","journal-title":"J. Clin. Oncol."},{"key":"10183_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00280-018-3663-z","volume":"82","author":"J Nishimura","year":"2018","unstructured":"Nishimura, J. et al. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Cancer Chemother. Pharmacol. 82, 707\u2013716 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10183_CR48","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1634\/theoncologist.2015-0038","volume":"20","author":"SM AlGizawy","year":"2015","unstructured":"AlGizawy, S. M., Essa, H. H. & Ahmed, B. M. Chemotherapy alone for patients with stage II\/III rectal cancer undergoing radical surgery. Oncologist 20, 752\u2013757 (2015).","journal-title":"Oncologist"},{"key":"10183_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00280-017-3243-7","volume":"79","author":"J Koike","year":"2017","unstructured":"Koike, J. et al. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II\/III rectal cancer: the FACT trial. Cancer Chemother. Pharmacol. 79, 519\u2013525 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10183_CR50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ejso.2016.02.014","volume":"42","author":"T Kamiya","year":"2016","unstructured":"Kamiya, T. et al. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Eur. J. Surg. Oncol. 42, 829\u2013835 (2016).","journal-title":"Eur. J. Surg. Oncol."},{"key":"10183_CR51","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2019.37.15_suppl.3504","volume":"37","author":"MT Seymour","year":"2019","unstructured":"Seymour, M. T. & Morton, D. on behalf of the International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. JCO 37, 3504\u20133504 (2019).","journal-title":"JCO"},{"key":"10183_CR52","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"10183_CR53","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.3390\/ijms231710135","volume":"23","author":"HJ Hwang","year":"2022","unstructured":"Hwang, H. J., Kim, N., Herman, A. B., Gorospe, M. & Lee, J.-S. Factors and pathways modulating endothelial cell senescence in vascular aging. Int J. Mol. Sci. 23, 10135 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"10183_CR54","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/nprot.2009.191","volume":"4","author":"F Debacq-Chainiaux","year":"2009","unstructured":"Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798\u20131806 (2009).","journal-title":"Nat. Protoc."},{"key":"10183_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).","journal-title":"Nat. Med."},{"key":"10183_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06860-4","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen, F. et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nat. Commun. 9, 4315 (2018).","journal-title":"Nat. Commun."},{"key":"10183_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13027","volume":"18","author":"Q Xu","year":"2019","unstructured":"Xu, Q. et al. Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. Aging Cell 18, e13027 (2019).","journal-title":"Aging Cell"},{"key":"10183_CR58","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.3390\/ijms22158163","volume":"22","author":"A Alberro","year":"2021","unstructured":"Alberro, A., Iparraguirre, L., Fernandes, A. & Otaegui, D. Extracellular vesicles in blood: sources, effects, and applications. Int. J. Mol. Sci. 22, 8163 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"10183_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12400","volume":"13","author":"R Nieuwland","year":"2024","unstructured":"Nieuwland, R. & Siljander, P. R. A beginner\u2019s guide to study extracellular vesicles in human blood plasma and serum. J. Extracell. Vesicles 13, e12400 (2024).","journal-title":"J. Extracell. Vesicles"},{"key":"10183_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203357","volume":"9","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Adipocyte-derived exosomal MTTP suppresses ferroptosis and promotes chemoresistance in colorectal cancer. Adv. Sci. 9, e2203357 (2022).","journal-title":"Adv. Sci."},{"key":"10183_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01168-8","volume":"19","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol. Cancer 19, 43 (2020).","journal-title":"Mol. Cancer"},{"key":"10183_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91\u201398 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"10183_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03753-7","volume":"25","author":"C Huang","year":"2025","unstructured":"Huang, C. et al. Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis. Cancer Cell Int. 25, 115 (2025).","journal-title":"Cancer Cell Int."},{"key":"10183_CR64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem 70, 503\u2013533 (2001).","journal-title":"Annu. Rev. Biochem"},{"key":"10183_CR65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/procel\/pwad045","volume":"15","author":"X Sheng","year":"2024","unstructured":"Sheng, X., Xia, Z., Yang, H. & Hu, R. The ubiquitin codes in cellular stress responses. Protein Cell 15, 157\u2013190 (2024).","journal-title":"Protein Cell"},{"key":"10183_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201701","volume":"9","author":"D Han","year":"2022","unstructured":"Han, D. et al. The E3 ligase TRIM4 facilitates SET ubiquitin-mediated degradation to enhance ER-\u03b1 action in breast cancer. Adv. Sci. 9, e2201701 (2022).","journal-title":"Adv. Sci."},{"key":"10183_CR67","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-022-05426-1","volume":"612","author":"M Schmitt","year":"2022","unstructured":"Schmitt, M. et al. Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. Nature 612, 347\u2013353 (2022).","journal-title":"Nature"},{"key":"10183_CR68","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian, L. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250\u2013254 (2017).","journal-title":"Nature"},{"key":"10183_CR69","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/j.freeradbiomed.2012.02.043","volume":"52","author":"S-E Yoo","year":"2012","unstructured":"Yoo, S.-E. et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free Radic. Biol. Med. 52, 1820\u20131827 (2012).","journal-title":"Free Radic. Biol. Med."},{"key":"10183_CR70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0006-291X(03)00734-4","volume":"305","author":"H Imai","year":"2003","unstructured":"Imai, H. et al. Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. Biochem Biophys. Res. Commun. 305, 278\u2013286 (2003).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10183_CR71","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180\u20131191 (2014).","journal-title":"Nat. Cell Biol."},{"key":"10183_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3164\/jcbn.09-94R","volume":"46","author":"H Imai","year":"2010","unstructured":"Imai, H. New strategy of functional analysis of PHGPx knockout mice model using transgenic rescue method and Cre-LoxP system. J. Clin. Biochem. Nutr. 46, 1\u201313 (2010).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10183_CR73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2008.07.005","volume":"8","author":"A Seiler","year":"2008","unstructured":"Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12\/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237\u2013248 (2008).","journal-title":"Cell Metab."},{"key":"10183_CR74","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","volume":"9","author":"X Sui","year":"2018","unstructured":"Sui, X. et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front. Pharmacol. 9, 1371 (2018).","journal-title":"Front. Pharmacol."},{"key":"10183_CR75","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10183-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:04:50Z","timestamp":1783641890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10183-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10183"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10183-2","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"932"}}